Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer
This randomized phase III trial studies metformin hydrochloride to see how well it works compared to placebo in preventing breast cancer in patients with atypical hyperplasia or in situ breast cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of metformin hydrochloride may prevent breast cancer.
Research Base: Alliance for Clinical Trials in Oncology
NCT ID: NCT01905046
NCI Protocol Number: A211102
Status: Recruiting
For more information see ClinicalTrials.gov
Interventions
Metformin hydrochloride; Placebo
Condition
Atypical Ductal Breast Hyperplasia, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Trial Type
Cancer Prevention
See a list of participating sites on ClinicalTrials.gov
